Prolonged Daily Temozolomide for Low-Grade Glioma

Inclusion Criteria: Histological confirmation of a low-grade glioma (astrocytoma, oligodendroglioma, or mixed oligoastrocytoma) Measurable disease on MRI Patients that have undergone recent resection for newly diagnosed or recurrent or progressive tumor are eligible if they have recovered from the effects of surgery. Patients with recurrent disease my have had one prior chemotherapy regimen Older than 18 years of age. Karnofsky performance status (KPS) performance score of > 70% Adequate hematologic, renal and liver functions, Life expectancy of greater than 12 weeks. Negative pregnancy test. Exclusion Criteria: Prior treatment with temozolomide Patients who are not neurologically stable Acute infection treated with intravenous antibiotics Non-malignant systemic disease Frequent vomiting, inability to swallow or a medical condition that could interfere with oral medication. Previous or concurrent malignancies at other sites, with the exception of surgically cured carcinoma in-situ of the cervix, and basal or squamous cell carcinoma of the skin. HIV positive or AIDS-related illness Pregnant or nursing women Patients with allergy to decarbazine.